About the Company
cytomx is an oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its probody technology platform. the company uses the platform to create development-stage proprietary cancer immunotherapies against clinically-validated targets, as well as to develop first-in-class investigational cancer therapeutics against novel targets. cytomx believes that its probody platform has the potential to improve the combined efficacy and safety profile of monoclonal antibody modalities, including cancer immunotherapies, antibody drug conjugates and t-cell-recruiting bispecific antibodies. probody therapeutics are designed to take advantage of unique conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues. investigational probody therapeutics are being developed that address clinically-validated cancer targets in immuno-oncology, such as pd-l1 against which o
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $CTMX News
CytomX Therapeutics Announces Milestone Achievement in PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas
SOUTH SAN FRANCISCO, Calif., March 18, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that ...
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Q4 2023 Earnings Call Transcript
Q4 2023 Earnings Call March 11, 2024 CytomX Therapeutics, Inc. isn’t one of the 30 most popular stocks among hedge funds at ...
CytomX Therapeutics Reports 2023 Financial Results and Provides Business Update
CX-904 (EGFRxCD3 T-cell engager) initial Phase 1a dose escalation data in solid tumors anticipated in the 2nd half of 2024 -- CX-2051 (EpCAM ...
CytomX falls as Bristol Myers ends deal for cancer therapy
CytomX Therapeutics (CTMX) stock fell as Bristol Myers Squibb (BMY) ended their research collaboration for a solid tumor drug ...
CytomX (CTMX) to Report Q4 Earnings: Here's What to Expect
The company has a four-quarter earnings surprise of 45.44%, on average. CytomX Therapeutics, Inc. Price and EPS Surprise CytomX Therapeutics, Inc. price-eps-surprise | CytomX Therapeutics ...
CytomX Therapeutics Inc (CTMX)
As of late, it has definitely been a great time to be an investor in CytomX Therapeutics, Inc. (NASDAQ:CTMX) . The stock has moved higher by 1.7% in the past month, while it is... There was not ...
J.P. Morgan Keeps Their Sell Rating on CytomX Therapeutics (CTMX)
In a report released yesterday, Anupam Rama from J.P. Morgan maintained a Sell rating on CytomX Therapeutics (CTMX – Research Report).
CytomX Therapeutics to Present at Upcoming March Investor Conferences
SOUTH SAN FRANCISCO, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that ...
CytomX Therapeutics Inc.: CytomX Therapeutics Reports 2023 Financial Results and Provides Business Update
March 11, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today reported full year 2023 financial results and ...
Loading the latest forecasts...